Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Pyridorin in Diabetic Nephropathy

ClinicalTrials.gov ID: NCT02156843

Public ClinicalTrials.gov record NCT02156843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes (PIONEER)

Study identification

NCT ID
NCT02156843
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
NephroGenex, Inc.
Industry
Enrollment
328 participants

Conditions and interventions

Interventions

  • Pyridorin Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2014
Primary completion
Nov 30, 2017
Completion
Feb 28, 2018
Last update posted
Mar 8, 2016

2014 – 2018

United States locations

U.S. sites
55
U.S. states
26
U.S. cities
50
Facility City State ZIP Site status
CSG Investigational Site (#157) Birmingham Alabama 35294
CSG Investigational Site (#130) Phoenix Arizona 85012
CSG Investigational Site (#150) Phoenix Arizona 85054
CSG Investigational Site (#145) Prescott Arizona 86301
CSG Investigational Site (#142) Tucson Arizona 85745
CSG Investigational Site (#160) Los Angeles California 90048
CSG Investigational Site (#143) Riverside California 92505
CSG Investigational Site (#159) Roseville California 95661
CSG Investigational Site (#153) Arvada Colorado 80002
CSG Investigational Site (#118) Aurora Colorado 80045
CSG Investigational Site (#120) Westminster Colorado 80031
CSG Investigational Site (#158) Waterbury Connecticut 06708
CSG Investigational Site (#156) Columbus Georgia 31901
CSG Investigational Site (#113) Chicago Illinois 60607
CSG Investigational Site (#102) Michigan City Indiana 46360
CSG Investigational Site (#115) New Orleans Louisiana 70112
CSG Investigational Site (#147) Greenbelt Maryland 20770
CSG Investigational Site (#117) Boston Massachusetts 02111
CSG Investigational Site (#114) Springfield Massachusetts 01107
CSG Investigational Site (#111) Detroit Michigan 48202
CSG Investigational Site (#134) Pontiac Michigan 48341
CSG Investigational Site (#162) Kansas City Missouri 64111
CSG Investigational Site (#152) Kansas City Missouri 64128
CSG Investigational Site (#141) Las Vegas Nevada 89115
CSG Investigational Site (#128) Buffalo New York 14215
CSG Investigational Site (#136) Northport New York 11768
CSG Investigational Site (#154) West Nyack New York 10994
CSG Investigational Site (#108) Asheville North Carolina 28801
CSG Investigational Site (#116) Charlotte North Carolina 28207
CSG Investigational Site (#125) Durham North Carolina 27710
CSG Investigational Site (#155) New Bern North Carolina 28562
CSG Investigational Site (#127) Winston-Salem North Carolina 27157
CSG Investigational Site (#124) Cincinnati Ohio 45267
CSG Investigational Site (#151) Cleveland Ohio 44106
CSG Investigational Site (#123) Cleveland Ohio 44195
CSG Investigational Site (#106) Columbus Ohio 43210
CSG Investigational Site (#148) Parma Heights Ohio 44130
CSG Investigational Site (#101) Philadelphia Pennsylvania 19104
CSG Investigational Site (#149) Pittsburgh Pennsylvania 15240
CSG Investigational Site (#146) Providence Rhode Island 02903
CSG Investigational Site (#131) Chattanooga Tennessee 37408
CSG Investigational Site (#105) Nashville Tennessee 37205
CSG Investigational Site (#119) Dallas Texas 75390
CSG Investigational Site (#139) Houston Texas 77004
CSG Investigational Site (#133) Houston Texas 77076
CSG Investigational Site (#109) Midland Texas 79707
CSG Investigational Site (#132) Salt Lake City Utah 84112
CSG Investigational Site (#107) Burlington Vermont 05401
CSG Investigational Site (#129) Charlottesville Virginia 22908
CSG Investigational Site (#137) Fairfax Virginia 22030
CSG Investigational Site (#103) Fairfax Virginia 22033
CSG Investigational Site (#104) Hampton Virginia 23666
CSG Investigational Site (#144) Richmond Virginia 23249
CSG Investigational Site (#121) Spokane Washington 99204
CSG Investigational Site (#122) Milwaukee Wisconsin 53295

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02156843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 8, 2016 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02156843 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →